In the clinical management of patients with MN, it is mandatory to exclude SLE, infections, drugs and malignancy, regardless of whether anti-PLA2R antibodies and/or anti-THSD7A antibodies are absent or present [12]. Here, THSD7A is linked to systemic lupus erythematosus.